Efficacy of a Recombinant Humanized Anti-IL-6 Receptor Monoclonal Antibody Compared to Hemoperfusion in Severe COVID-19 Pneumonia: Ambispective Cohort Study

被引：0
|
作者：
Thammavaranucupt, Kanin [1 ]
Jayanama, Kulapong [1 ]
Spanuchart, Ittikorn [2 ]
机构：
[1] Chakri Naruebodin Med Inst, Bang Phli, Thailand
[2] Mahidol Univ, Fac Med, Ramathibodi Hosp, Bangkok, Thailand
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
FR-PO016
引用
收藏
页码：330 / 330
页数：1
相关论文
共 50 条
  • [31] Circulating Proteins Associated with Anti-IL6 Receptor Therapeutic Resistance in the Sera of Patients with Severe COVID-19
    Michot, Jean-Marie
    Dozio, Vito
    Rohmer, Julien
    Pommeret, Fanny
    Roumier, Mathilde
    Yu, Haochen
    Sklodowki, Kamil
    Danlos, Francois-Xavier
    Ouali, Kaissa
    Kishazi, Edina
    Naigeon, Marie
    Griscelli, Franck
    Gachot, Bertrand
    Groh, Matthieu
    Bacciarello, Giulia
    Stoclin, Annabelle
    Willekens, Christophe
    Sakkal, Madona
    Bayle, Arnaud
    Zitvogel, Laurence
    Silvin, Aymeric
    Soria, Jean-Charles
    Barlesi, Fabrice
    Beeler, Kristina
    Andre, Fabrice
    Vasse, Marc
    Chaput, Nathalie
    Ackermann, Felix
    Escher, Claudia
    Marabelle, Aurelien
    JOURNAL OF PROTEOME RESEARCH, 2024, 23 (11) : 5001 - 5015
  • [32] Anti-CD6 humanized monoclonal antibody itolizumab, halts disease progression and severity of acute respiratory distress syndrome in COVID-19 disease: A case study
    Thacker, Hemant P.
    Dhekane, Amit
    Wadhwa, Nivedita
    Patil, Shalaka
    INDIAN JOURNAL OF RESPIRATORY CARE, 2021, 10 (01) : 112 - 115
  • [33] The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19( vol 89 , 106241 , 2024)
    Foong, Kap Sum
    JOURNAL OF INFECTION, 2024, 89 (06)
  • [34] Efficacy and safety of tocilizumab in monotherapy, an anti-IL-6 receptor monoclonal antibody, in patients with active rheumatoid arthritis: Results from a 24 week double-blind phase III study
    Nishimoto, N.
    Miyasaka, N.
    Yamamoto, K.
    Kawai, S.
    Takeuchi, T.
    Azuma, J.
    Kishimoto, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 59 - 59
  • [35] Long-term therapeutic experience of humanized anti-IL-6 receptor monoclonal antibody (aIL-6R Mab) in systemic-onset juvenile idiopathic arthritis (So-JIA).
    Yokota, S
    Imagawa, T
    Miyamae, T
    Mori, M
    Nishimoto, N
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S438 - S438
  • [36] A dose finding study of a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, MRA in multicentric Castleman's disease.
    Yoshizaki, K
    Kanakura, Y
    Aozasa, K
    Johkoh, T
    Nakamura, M
    Kodama, F
    Kumagai, S
    Asaoku, H
    Kishimoto, T
    Nishimoto, N
    BLOOD, 2002, 100 (11) : 363A - 363A
  • [37] Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
    Della-Torre, Emanuel
    Campochiaro, Corrado
    Cavalli, Giulio
    De Luca, Giacomo
    Napolitano, Angela
    La Marca, Salvatore
    Boffini, Nicola
    Da Prat, Valentina
    Di Terlizzi, Gaetano
    Lanzillotta, Marco
    Rovere Querini, Patrizia
    Ruggeri, Annalisa
    Landoni, Giovanni
    Tresoldi, Moreno
    Ciceri, Fabio
    Zangrillo, ALberto
    De Cobelli, Francesco
    Dagna, Lorenzo
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (10) : 1277 - 1285
  • [38] A multi-center, randomized, double blind, placebo-controlled study of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in children with systemic juvenile idiopathic arthritis
    Yokota, S.
    Imagawa, T.
    Mori, M.
    Takei, S.
    Kawano, Y.
    Iwata, N.
    Tomiita, M.
    Miyosh, M.
    Aihara, Y.
    Murata, T.
    Abukawa, D.
    Nishimoto, N.
    Kishimoto, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 59 - 60
  • [39] Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study
    Potere, Nicola
    Di Nisio, Marcello
    Cibelli, Donatella
    Scurti, Rosa
    Frattari, Antonella
    Porreca, Ettore
    Abbate, Antonio
    Parruti, Giustino
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (02) : 271 - +
  • [40] A CASE REPORT OF RENAL FAILURE AND SEVERE SYSTEMIC INFLAMMATION CAUSED BY HHV-8-NEGATIVE MULTICENTRIC CASTLEMAN DISEASE SUCCESSFULLY TREATED WITH TOCILIZUMAB, AN ANTI-IL-6 RECEPTOR MONOCLONAL ANTIBODY
    Biltibo, Eden
    Lammers, Philip E.
    ANTICANCER RESEARCH, 2016, 36 (12) : 6712 - 6713
12345